Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810

Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases

(2016) L. Borradori et al.   BRITISH JOURNAL OF DERMATOLOGY

Anti-programmed cell death-1 therapy in nonmelanoma skin cancer

(2016) J.K. Winkler et al.   BRITISH JOURNAL OF DERMATOLOGY

Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma

(2016) Ximena Bonilla et al.   NATURE GENETICS

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma

(2016) Paul T. Nghiem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor Regression and Allograft Rejection after Administration of Anti–PD-1

(2016) Evan J. Lipson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Personalized Oncology Meets Immunology: The Path toward Precision Immunotherapy

(2016) R. Mandal et al.   Cancer Discovery

A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor

(2016) Anne Lynn S. Chang et al.   JAMA Dermatology

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas

(2015) S. Q. Wong et al.   CANCER RESEARCH

Hedgehog Pathway Inhibitors Promote Adaptive Immune Responses in Basal Cell Carcinoma

(2015) A. Otsuka et al.   CLINICAL CANCER RESEARCH

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational Landscape of Aggressive Cutaneous Squamous Cell Carcinoma

(2014) C. R. Pickering et al.   CLINICAL CANCER RESEARCH

Cancer-Testis Antigens and Immunosurveillance in Human Cutaneous Squamous Cell and Basal Cell Carcinomas

(2010) A. Walter et al.   CLINICAL CANCER RESEARCH